Responses
Regular and young investigator award abstracts
Clinical trials in progress
370 Pharmacodynamic assessment of a novel FAP-targeted 4–1BB agonist, administered as single agent and in combination with atezolizumab to patients with advanced solid tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.
